Search

Displaying results 2431 - 2440 of 4591 in total
  1. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. … [A203369] Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment

  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  3. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

  4. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan.

  5. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.

  6. Drug

    Cilnidipine

    go.drugbank.com/drugs/DB09232
    Investigational

    It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved in 1995.

  7. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  8. Drug

    Ulevostinag

    go.drugbank.com/drugs/DB14721
    Investigational

    Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). … Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear

  9. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was approved by

  10. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    It was first approved by the European Commission in January 2018. … [A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII.